Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jan 27:2020:8545643.
doi: 10.1155/2020/8545643. eCollection 2020.

Effects of BRCA Germline Mutations on Triple-Negative Breast Cancer Prognosis

Katarzyna Pogoda  1 , Anna Niwińska  1 , Elżbieta Sarnowska  2 , Dorota Nowakowska  3 , Agnieszka Jagiełło-Gruszfeld  1 , Janusz Siedlecki  2 , Zbigniew Nowecki  1
Affiliations

Effects of BRCA Germline Mutations on Triple-Negative Breast Cancer Prognosis

Katarzyna Pogoda et al. J Oncol. .

Abstract

Germline BRCA1 and BRCA2 mutations confer an increased lifetime risk for breast cancer and ovarian cancer. Several studies have investigated prognosis among BRCA1/2 mutation carriers and noncarriers, but the prognostic impact on outcomes of breast cancer patients has not been determined. The aim of this study was to determine the prognosis of TNBC patients with and without BRCA1/2 germline mutation. Among 502 patients diagnosed with TNBC between 2005 and 2008, 124 patients with a strong family history of breast cancer or ovarian cancer as well as TNBC patients diagnosed under 45 years were referred to the Genetic Counseling Unit for genetic counselling and genetic tests. In 30 (24%) of them, the BRCA1/2 mutation was detected (the most common 5382insC in 18 (60%) patients). The median follow-up of the entire group was 60 months. BRCA1/2 mutation carriers were statistically significantly younger at TNBC diagnosis compared with nonmutation patients (41 vs 47 years, respectively). Patients with the BRCA1/2 mutation had smaller tumors (stage I: 47% vs 24.5% in noncarriers), but there was no significant difference in the regional nodal status (58.5-63% with cN0). Contralateral breast cancer developed in 26.5% of BRCA1/2 mutation carriers and in 14% of noncarriers. Other primary cancers were also slightly more common in BRCA1/2 mutation carriers (16.5% vs 9.5%). The performed analysis did not show any significant differences between the groups in recurrence-free survival (p=0.312). There was no significant difference between patients with or without BRCA1/2 mutation as regards overall survival (p=0.649) and the risk of TNBC death (p=0.333). The survival from detection of metastases was similar in two groups (p=0.865). Our study demonstrated that the BRCA1 mutation does not affect TNBC patients' outcomes.

PubMed Disclaimer

Conflict of interest statement

The authors declare that there are no conflicts of interest regarding the publication of this article.

Figures

Figure 1
Figure 1
Risk of recurrence in TNBC patients depending on the BRCA mutation status.
Figure 2
Figure 2
Risk of death in TNBC patients depending on the BRCA mutation status.
Figure 3
Figure 3
Relationship between the presence of the BRCA1/2 mutation and the risk of death due to TNBC.
Figure 4
Figure 4
Survival time counted from relapse depending on the BRCA1/2 mutation status.
See this image and copyright information in PMC

References

    1. Wang F., Fang Q., Ge Z., Yu N., Xu S., Fan X. Common BRCA1 and BRCA2 mutations in breast cancer families: a meta-analysis from systematic review. Molecular Biology Reports. 2012;39(3):2109–2118. doi: 10.1007/s11033-011-0958-0. - DOI - PubMed
    1. Tung N., Battelli C., Allen B., et al. Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel. Cancer. 2015;121(1):25–33. doi: 10.1002/cncr.29010. - DOI - PubMed
    1. Zhu Y., Wu J., Zhang C., et al. BRCA mutations and survival in breast cancer: an updated systematic review and meta-analysis. Oncotarget. 2016;7:70113–70127. doi: 10.18632/oncotarget.12158. - DOI - PMC - PubMed
    1. Warner E., Foulkes W., Goodwin P., et al. Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer. JNCI Journal of the National Cancer Institute. 1999;91(14):1241–1247. doi: 10.1093/jnci/91.14.1241. - DOI - PubMed
    1. Zhang J., Pei R., Pang Z., et al. Prevalence and characterization of BRCA1 and BRCA2 germline mutations in Chinese women with familial breast cancer. Breast Cancer Research and Treatment. 2012;132(2):421–428. doi: 10.1007/s10549-011-1596-x. - DOI - PubMed

LinkOut - more resources